Table 2.
Correlations between HOXD9 protein expression with clinical features in 40 ATC patients
| Variables | Cases | HOXD9 | χ2 value | P value | |
|---|---|---|---|---|---|
| Low (n = 20) | High (n = 20) | ||||
| Sex | 1.9048 | 0.1675 | |||
| Men | 28 | 12 | 16 | ||
| Women | 12 | 8 | 4 | ||
| Ages | 0.1023 | 0.7491 | |||
| < 60 | 17 | 8 | 9 | ||
| ≥ 60 | 23 | 12 | 11 | ||
| Primary tumor size | 3.9560 | 0.0467* | |||
| < 6 cm | 14 | 4 | 10 | ||
| ≥ 6 cm | 26 | 16 | 10 | ||
| Lymph node metastasis | 0.4167 | 0.5186 | |||
| N0 | 16 | 7 | 9 | ||
| N1 | 24 | 13 | 11 | ||
| Distant metastasis | 4.2857 | 0.0384* | |||
| M0 | 28 | 17 | 11 | ||
| M1 | 12 | 3 | 9 | ||
| Stage (AJCC, 2010) | 8.19 | 0.0167* | |||
| IVA | 14 | 10 | 4 | ||
| IVB | 12 | 2 | 10 | ||
| IVC | 14 | 8 | 6 | ||
The median value of HOXD9 mRNA expression was used as the cutoff for dividing patients into a high-expression group (n = 20) and a low-expression group (n = 20). P value when expression levels were compared using the Pearson Chi-square test. Bold values have statistical significance. *P < 0.05